Metastatic Colorectal Cancers Completed Phase 2 Trials for Capecitabine (DB01101)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01471353Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal CancerTreatment
NCT02083653Sym004 vs Standard of Care in Subjects With Metastatic Colorectal CancerTreatment
NCT00875771Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsTreatment
NCT00205322Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal CancerTreatment
NCT00254137Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.Treatment
NCT003456961stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.Treatment
NCT00378066Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon CancerTreatment
NCT00514761Phase II Efficacy Study of AZD6244 in Colorectal CancerTreatment
NCT00574171Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal AdenocarcinomaTreatment
NCT01022541Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal CancerTreatment
NCT01024504Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal CancerTreatment
NCT01472770A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal CancerTreatment